Figure 5.

Inhibition of tumor growth by ADRB antagonists. Tumor volumes reached after subcutaneous injections of 10⁶ 786-O wild type cells (n = 9–10) and intraperitoneal treatment with 10 mg/Kg/day Vehicle (■), propranolol (●), or ICI (♦), in 10–12-week-old male NOD/SCID mice. (A). (VHL-disease scenario) Systemic treatment started along the first five days after tumor implantation; or (B). (Classical in vivo cancer research assay) when average tumor reached 100 mm³ volume. (C). Average weights of the collected tumors. (D). Immunohistochemical detection of HIF-2α in the ccRCC 786-O tumor xenografts. Cell nuclei were counterstained with hematoxylin. Scale bars represent 100 µm. (C,D) belong to the “(B). Classical in vivo cancer research assay” approach. Abbreviations: V, P, and I for vehicle, propranolol, and ICI, respectively. Error bars denote ± SEM for each time. Student’s t-test: * p < 0.05; ** p <0.01; *** p < 0.001.